Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Phase 3 Ophthalmology Trial in Japan (jRCT2080224036)
jRCT2080224036Phase 3Completed
- Start
- Sep 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of aflibercept. Started Sep 2018; status: completed.
02
Drugs
aflibercept
Beyond the preview
Go deeper on jRCT2080224036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224036.